Literature DB >> 2336463

Methods for analysis of censored tumor growth delay data.

M Stuschke1, V Budach, M Bamberg, W Budach.   

Abstract

Growth delay times of experimental tumors after subcurative therapy may be censored because of intercurrent death of the host animals, limitations of the follow-up period, or the number of cured tumors. Under the general assumptions of log-normally distributed data and independence of the censoring event and the therapy effect, it is shown using computer simulations that the estimate of the median growth delay according to the product limit method of Kaplan and Meier, which allows inclusion of censored data, is unbiased. Omission of censored growth delay times from incomplete accrued data often leads to biased estimates. The power of statistical tests for qualitative comparison of two therapy groups with incomplete sets of data from growth assays was also studied. In the absence of censoring, the power of the different tests is about the same. At higher censoring rates of 40%, however, tests applicable to censored data (log-rank test, Gehan-Wilcoxon test) have a markedly higher power than tests applied to the reduced set of complete observed growth delays (mu test, t test). Although complete observation of tumor regrowth should be strived for, growth delay experiments with very delicate animal tumor models can easily result in censored data. The methods presented permit quantitative and qualitative analysis of growth delay data up to a censoring rate of over 30%, if growth delays and censoring events are independent.

Entities:  

Mesh:

Year:  1990        PMID: 2336463

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  5 in total

1.  Modeling human choroidal melanoma xenograft growth in immunocompromised rodents to assess treatment efficacy.

Authors:  Rod D Braun; Kerry S Vistisen
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-04       Impact factor: 4.799

2.  Assessing cytotoxic treatment effects in preclinical tumor xenograft models.

Authors:  Jianrong Wu; Peter J Houghton
Journal:  J Biopharm Stat       Date:  2009-09       Impact factor: 1.051

3.  Confidence intervals for the difference of median failure times applied to censored tumor growth delay data.

Authors:  Jianrong Wu
Journal:  Stat Biopharm Res       Date:  2012-01-24       Impact factor: 1.452

4.  Analysing Tumour Growth Delay Data from Animal Irradiation Experiments with Deviations from the Prescribed Dose.

Authors:  Leonhard Karsch; Elke Beyreuther; Doreen Eger Passos; Jörg Pawelke; Steffen Löck
Journal:  Cancers (Basel)       Date:  2019-08-31       Impact factor: 6.639

5.  Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.

Authors:  W Budach; V Budach; M Stuschke; B Schmauder; P Reipke; M E Scheulen
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.